{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:24:53Z","timestamp":1773181493980,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K09471"],"award-info":[{"award-number":["JP18K09471"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K09745"],"award-info":[{"award-number":["JP21K09745"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011746","name":"NOVARTIS Foundation (Japan) for the Promotion of Science","doi-asserted-by":"publisher","award":["AT"],"award-info":[{"award-number":["AT"]}],"id":[{"id":"10.13039\/501100011746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000950","name":"Alcon Foundation","doi-asserted-by":"publisher","award":["AT"],"award-info":[{"award-number":["AT"]}],"id":[{"id":"10.13039\/100000950","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AMO Japan Research Grants","award":["AT"],"award-info":[{"award-number":["AT"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-022-05600-1","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T07:02:36Z","timestamp":1646118156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Increased vitreous levels of B cell activation factor (BAFF) and soluble interleukin-6 receptor in patients with macular edema due to uveitis related to Beh\u00e7et\u2019s disease and sarcoidosis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-6146","authenticated-orcid":false,"given":"Atsunobu","family":"Takeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyo","family":"Yawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Notomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keijiro","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Hisatomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"5600_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2147\/OPTH.S180580","volume":"13","author":"H Massa","year":"2019","unstructured":"Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD (2019) Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol 13:1761\u20131777. https:\/\/doi.org\/10.2147\/OPTH.S180580","journal-title":"Clin Ophthalmol"},{"key":"5600_CR2","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","volume":"88","author":"OM Durrani","year":"2004","unstructured":"Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88:1159\u20131162. https:\/\/doi.org\/10.1136\/bjo.2003.037226","journal-title":"Br J Ophthalmol"},{"key":"5600_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ophtha.2015.10.028","volume":"123","author":"AD Dick","year":"2016","unstructured":"Dick AD, Tundia N, Sorg R, Zhao C, Chao J, Joshi A, Skup M (2016) Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 123:655\u2013662. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.028","journal-title":"Ophthalmology"},{"key":"5600_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/DDDT.S166092","volume":"13","author":"S Koronis","year":"2019","unstructured":"Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG (2019) Update in treatment of uveitic macular edema. Drug Des Dev Ther 13:667\u2013680. https:\/\/doi.org\/10.2147\/DDDT.S166092","journal-title":"Drug Des Dev Ther"},{"key":"5600_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09273948.2019.1576910","volume":"27","author":"M Accorinti","year":"2019","unstructured":"Accorinti M, Okada AA, Smith JR, Gilardi M (2019) Epidemiology of macular edema in uveitis. Ocul Immunol Inflamm 27:169\u2013180. https:\/\/doi.org\/10.1080\/09273948.2019.1576910","journal-title":"Ocul Immunol Inflamm"},{"key":"5600_CR6","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","volume":"113","author":"CW Lardenoye","year":"2006","unstructured":"Lardenoye CW, van Kooij B, Rothova A (2006) Impact of macular edema on visual acuity in uveitis. Ophthalmology 113:1446\u20131449. https:\/\/doi.org\/10.1016\/j.ophtha.2006.03.027","journal-title":"Ophthalmology"},{"key":"5600_CR7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/bjophthalmol-2012-303052","volume":"97","author":"MR Munk","year":"2013","unstructured":"Munk MR, Kiss CG, Steiner I, Sulzbacher F, Roberts P, Kroh M, Montuoro A, Simader C, Schmidt-Erfurth U (2013) Systematic correlation of morphologic alterations and retinal function in eyes with uveitis-associated cystoid macular oedema during development, resolution and relapse. Br J Ophthalmol 97:1289\u20131296. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-303052","journal-title":"Br J Ophthalmol"},{"key":"5600_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/APO.0000000000000352","volume":"10","author":"YH Li","year":"2021","unstructured":"Li YH, Hsu SL, Sheu SJ (2021) A review of local therapy for the management of cystoid macular edema in uveitis. Asia Pac J Ophthalmol (Phila) 10:87\u201392. https:\/\/doi.org\/10.1097\/APO.0000000000000352","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"5600_CR9","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2017.5103","volume":"317","author":"JH Kempen","year":"2017","unstructured":"Writing Committee for the Multicenter Uveitis Steroid Treatment T, Follow-up Study Research G, Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, Thorne JE, Jabs DA (2017) Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA 317:1993\u20132005. https:\/\/doi.org\/10.1001\/jama.2017.5103","journal-title":"JAMA"},{"issue":"588\u2013595","key":"5600_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.023","volume":"121","author":"MH Levin","year":"2014","unstructured":"Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Kempen JH, Systemic Immunosuppressive Therapy for Eye Diseases Cohort S (2014) Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology 121(588\u2013595):e581. https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.023","journal-title":"Ophthalmology"},{"key":"5600_CR11","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3389\/fimmu.2020.01431","volume":"11","author":"A Takeda","year":"2020","unstructured":"Takeda A, Yanai R, Murakami Y, Arima M, Sonoda KH (2020) New insights into immunological therapy for retinal disorders. Front Immunol 11:1431. https:\/\/doi.org\/10.3389\/fimmu.2020.01431","journal-title":"Front Immunol"},{"key":"5600_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/ceo.13511","volume":"47","author":"M Hassan","year":"2019","unstructured":"Hassan M, Karkhur S, Bae JH, Halim MS, Ormaechea MS, Onghanseng N, Nguyen NV, Afridi R, Sepah YJ, Do DV, Nguyen QD (2019) New therapies in development for the management of non-infectious uveitis: a review. Clin Exp Ophthalmol 47:396\u2013417. https:\/\/doi.org\/10.1111\/ceo.13511","journal-title":"Clin Exp Ophthalmol"},{"key":"5600_CR13","first-page":"2003","volume":"17","author":"NV Valentincic","year":"2011","unstructured":"Valentincic NV, de Groot-Mijnes JD, Kraut A, Korosec P, Hawlina M, Rothova A (2011) Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol Vis 17:2003\u20132010","journal-title":"Mol Vis"},{"key":"5600_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajo.2006.02.052","volume":"142","author":"B van Kooij","year":"2006","unstructured":"van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD (2006) Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 142:192\u2013194. https:\/\/doi.org\/10.1016\/j.ajo.2006.02.052","journal-title":"Am J Ophthalmol"},{"key":"5600_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","volume":"200","author":"N Vegas-Revenga","year":"2019","unstructured":"Vegas-Revenga N, Calvo-Rio V, Mesquida M, Adan A, Hernandez MV, Beltran E, Valls Pascual E, Diaz-Valle D, Diaz-Cordoves G, Hernandez-Garfella M, Martinez-Costa L, Calvo I, Atanes A, Linares LF, Modesto C, Gonzalez-Vela C, Demetrio-Pablo R, Aurrecoechea E, Cordero M, Dominguez-Casas LC, Atienza-Mateo B, Martin-Varillas JL, Loricera J, Palmou-Fontana N, Hernandez JL, Gonzalez-Gay MA, Blanco R (2019) Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol 200:85\u201394. https:\/\/doi.org\/10.1016\/j.ajo.2018.12.019","journal-title":"Am J Ophthalmol"},{"key":"5600_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1167\/tvst.8.5.32","volume":"8","author":"M Mesquida","year":"2019","unstructured":"Mesquida M, Drawnel F, Lait PJ, Copland DA, Stimpson ML, Llorenc V, Sainz de la Maza M, Adan A, Widmer G, Strassburger P, Fauser S, Dick AD, Lee RWJ, Molins B (2019) Modelling macular edema: the effect of IL-6 and IL-6R blockade on human blood-retinal barrier integrity in vitro. Transl Vis Sci Technol 8:32. https:\/\/doi.org\/10.1167\/tvst.8.5.32","journal-title":"Transl Vis Sci Technol"},{"key":"5600_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pathophys.2017.05.005","volume":"24","author":"F Zahir-Jouzdani","year":"2017","unstructured":"Zahir-Jouzdani F, Atyabi F, Mojtabavi N (2017) Interleukin-6 participation in pathology of ocular diseases. Pathophysiology 24:123\u2013131. https:\/\/doi.org\/10.1016\/j.pathophys.2017.05.005","journal-title":"Pathophysiology"},{"key":"5600_CR18","doi-asserted-by":"publisher","unstructured":"Kunimi K, Usui Y, Asakage M, Maehara C, Tsubota K, Mitsuhashi R, Umazume A, Kezuka T, Sakai JI, Goto H (2020) Anti-TNF-alpha therapy for refractory uveitis associated with Behcet\u2019s syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm 1-8.https:\/\/doi.org\/10.1080\/09273948.2020.1791346","DOI":"10.1080\/09273948.2020.1791346"},{"key":"5600_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/09273948.2019.1604974","volume":"28","author":"AM Abu El-Asrar","year":"2020","unstructured":"Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, Gikandi PW, Opdenakker G, Van Damme J, Struyf S (2020) Local cytokine expression profiling in patients with specific autoimmune uveitic entities. Ocul Immunol Inflamm 28:453\u2013462. https:\/\/doi.org\/10.1080\/09273948.2019.1604974","journal-title":"Ocul Immunol Inflamm"},{"key":"5600_CR20","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41433-019-0693-7","volume":"34","author":"AM Abu El-Asrar","year":"2020","unstructured":"Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, Gikandi PW, Opdenakker G, Van Damme J, Struyf S (2020) Soluble cytokine receptor levels in aqueous humour of patients with specific autoimmune uveitic entities: sCD30 is a biomarker of granulomatous uveitis. Eye (Lond) 34:1614\u20131623. https:\/\/doi.org\/10.1038\/s41433-019-0693-7","journal-title":"Eye (Lond)"},{"key":"5600_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrrheum.2017.22","volume":"13","author":"M Croft","year":"2017","unstructured":"Croft M, Siegel RM (2017) Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol 13:217\u2013233. https:\/\/doi.org\/10.1038\/nrrheum.2017.22","journal-title":"Nat Rev Rheumatol"},{"key":"5600_CR22","first-page":"1078","volume":"335","author":"International Study Group for Behcet\u2019s Disease","year":"1990","unstructured":"International Study Group for Behcet\u2019s Disease (1990) Criteria for diagnosis of Behcet\u2019s disease. Lancet 335:1078\u20131080","journal-title":"Lancet"},{"key":"5600_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10384-012-0158-z","volume":"56","author":"N Ohguro","year":"2012","unstructured":"Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M (2012) The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol 56:432\u2013435. https:\/\/doi.org\/10.1007\/s10384-012-0158-z","journal-title":"Jpn J Ophthalmol"},{"key":"5600_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509\u2013516","journal-title":"Am J Ophthalmol"},{"key":"5600_CR25","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1167\/iovs.15-17465","volume":"56","author":"A Takeda","year":"2015","unstructured":"Takeda A, Yoshikawa H, Fukuhara T, Hikita S, Hijioka K, Otomo T, Arita R, Hisatomi T, Kimura K, Yoshida S, Kawano Y, Sonoda KH, Ishibashi T (2015) Distinct profiles of soluble cytokine receptors between B-cell vitreoretinal lymphoma and uveitis. Invest Ophthalmol Vis Sci 56:7516\u20137523. https:\/\/doi.org\/10.1167\/iovs.15-17465","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5600_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.2","volume":"5","author":"JR Smith","year":"2016","unstructured":"Smith JR, Stempel AJ, Bharadwaj A, Appukuttan B (2016) Involvement of B cells in non-infectious uveitis. Clin Transl Immunol 5:e63. https:\/\/doi.org\/10.1038\/cti.2016.2","journal-title":"Clin Transl Immunol"},{"key":"5600_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102736","volume":"20","author":"T Mockel","year":"2021","unstructured":"Mockel T, Basta F, Weinmann-Menke J, Schwarting A (2021) B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev 20:102736. https:\/\/doi.org\/10.1016\/j.autrev.2020.102736","journal-title":"Autoimmun Rev"},{"key":"5600_CR28","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/rheumatology\/ket186","volume":"52","author":"I Ueda-Hayakawa","year":"2013","unstructured":"Ueda-Hayakawa I, Tanimura H, Osawa M, Iwasaka H, Ohe S, Yamazaki F, Mizuno K, Okamoto H (2013) Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity. Rheumatology (Oxford) 52:1658\u20131666. https:\/\/doi.org\/10.1093\/rheumatology\/ket186","journal-title":"Rheumatology (Oxford)"},{"key":"5600_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043588","volume":"7","author":"A Saussine","year":"2012","unstructured":"Saussine A, Tazi A, Feuillet S, Rybojad M, Juillard C, Bergeron A, Dessirier V, Bouhidel F, Janin A, Bensussan A, Bagot M, Bouaziz JD (2012) Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS ONE 7:e43588. https:\/\/doi.org\/10.1371\/journal.pone.0043588","journal-title":"PLoS ONE"},{"key":"5600_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-3083.2012.02694.x","volume":"75","author":"Y Sumita","year":"2012","unstructured":"Sumita Y, Murakawa Y, Sugiura T, Wada Y, Nagai A, Yamaguchi S (2012) Elevated BAFF levels in the cerebrospinal fluid of patients with neuro-Behcet\u2019s disease: BAFF is correlated with progressive dementia and psychosis. Scand J Immunol 75:633\u2013640. https:\/\/doi.org\/10.1111\/j.1365-3083.2012.02694.x","journal-title":"Scand J Immunol"},{"key":"5600_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/IAE.0000000000001563","volume":"38","author":"AF Lasave","year":"2018","unstructured":"Lasave AF, You C, Ma L, Abusamra K, Lamba N, Valdes Navarro M, Meese H, Foster CS (2018) Long-term outcomes of rituximab therapy in patients with noninfectious posterior uveitis refractory to conventional immunosuppressive therapy. Retina 38:395\u2013402. https:\/\/doi.org\/10.1097\/IAE.0000000000001563","journal-title":"Retina"},{"key":"5600_CR32","doi-asserted-by":"publisher","first-page":"17050","DOI":"10.1002\/jcp.28445","volume":"234","author":"AG Shabgah","year":"2019","unstructured":"Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M (2019) The role of BAFF and APRIL in rheumatoid arthritis. J Cell Physiol 234:17050\u201317063. https:\/\/doi.org\/10.1002\/jcp.28445","journal-title":"J Cell Physiol"},{"key":"5600_CR33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s10165-012-0694-x","volume":"23","author":"TA Gheita","year":"2013","unstructured":"Gheita TA, Raafat H, Khalil H, Hussein H (2013) Serum level of APRIL\/BLyS in Behcet\u2019s disease patients: clinical significance in uveitis and disease activity. Mod Rheumatol 23:542\u2013546. https:\/\/doi.org\/10.1007\/s10165-012-0694-x","journal-title":"Mod Rheumatol"},{"key":"5600_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cytogfr.2013.12.011","volume":"25","author":"M Chen","year":"2014","unstructured":"Chen M, Lin X, Liu Y, Li Q, Deng Y, Liu Z, Brand D, Guo Z, He X, Ryffel B, Zheng SG (2014) The function of BAFF on T helper cells in autoimmunity. Cytokine Growth Factor Rev 25:301\u2013305. https:\/\/doi.org\/10.1016\/j.cytogfr.2013.12.011","journal-title":"Cytokine Growth Factor Rev"},{"key":"5600_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.570920","volume":"11","author":"R Quan","year":"2020","unstructured":"Quan R, Chen C, Yan W, Zhang Y, Zhao X, Fu Y (2020) BAFF blockade attenuates inflammatory responses and intestinal barrier dysfunction in a murine endotoxemia model. Front Immunol 11:570920. https:\/\/doi.org\/10.3389\/fimmu.2020.570920","journal-title":"Front Immunol"},{"key":"5600_CR36","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1167\/iovs.16-19758","volume":"57","author":"AM Abu El-Asrar","year":"2016","unstructured":"Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, Mousa A, Opdenakker G, Van Damme J, Struyf S (2016) The cytokine interleukin-6 and the chemokines CCL20 and CXCL13 are novel biomarkers of specific endogenous uveitic entities. Invest Ophthalmol Vis Sci 57:4606\u20134613. https:\/\/doi.org\/10.1167\/iovs.16-19758","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5600_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","volume":"70","author":"J Wolf","year":"2014","unstructured":"Wolf J, Rose-John S, Garbers C (2014) Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 70:11\u201320. https:\/\/doi.org\/10.1016\/j.cyto.2014.05.024","journal-title":"Cytokine"},{"key":"5600_CR38","doi-asserted-by":"publisher","unstructured":"Mustafi D, Do BK, Rodger DC, Rao NA (2020) Relationship of epiretinal membrane formation and macular edema development in a large cohort of uveitic eyes. Ocul Immunol Inflamm 1-7.https:\/\/doi.org\/10.1080\/09273948.2019.1704026","DOI":"10.1080\/09273948.2019.1704026"},{"issue":"78\u201386","key":"5600_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.01.032","volume":"154","author":"H Nazari","year":"2012","unstructured":"Nazari H, Dustin L, Heussen FM, Sadda S, Rao NA (2012) Morphometric spectral-domain optical coherence tomography features of epiretinal membrane correlate with visual acuity in patients with uveitis. Am J Ophthalmol 154(78\u201386):e71. https:\/\/doi.org\/10.1016\/j.ajo.2012.01.032","journal-title":"Am J Ophthalmol"},{"key":"5600_CR40","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ajo.2014.01.020","volume":"157","author":"B Lehpamer","year":"2014","unstructured":"Lehpamer B, Moshier E, Pahk P, Goldberg N, Ackert J, Godbold J, Jabs DA (2014) Epiretinal membranes in uveitic macular edema: effect on vision and response to therapy. Am J Ophthalmol 157:1048\u20131055. https:\/\/doi.org\/10.1016\/j.ajo.2014.01.020","journal-title":"Am J Ophthalmol"},{"key":"5600_CR41","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/bjo.2006.092965","volume":"90","author":"P Tranos","year":"2006","unstructured":"Tranos P, Scott R, Zambarakji H, Ayliffe W, Pavesio C, Charteris DG (2006) The effect of pars plana vitrectomy on cystoid macular oedema associated with chronic uveitis: a randomised, controlled pilot study. Br J Ophthalmol 90:1107\u20131110. https:\/\/doi.org\/10.1136\/bjo.2006.092965","journal-title":"Br J Ophthalmol"},{"key":"5600_CR42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajo.2018.03.031","volume":"190","author":"CR Henry","year":"2018","unstructured":"Henry CR, Becker MD, Yang Y, Davis JL (2018) Pars plana vitrectomy for the treatment of uveitis. Am J Ophthalmol 190:142\u2013149. https:\/\/doi.org\/10.1016\/j.ajo.2018.03.031","journal-title":"Am J Ophthalmol"},{"key":"5600_CR43","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cytogfr.2008.08.001","volume":"19","author":"KX Wang","year":"2008","unstructured":"Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19:333\u2013345. https:\/\/doi.org\/10.1016\/j.cytogfr.2008.08.001","journal-title":"Cytokine Growth Factor Rev"},{"key":"5600_CR44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10875-012-9820-y","volume":"33","author":"IH Bassyouni","year":"2013","unstructured":"Bassyouni IH, El-Wakd MM, Bassyouni RH (2013) Soluble levels of osteopontin in patients with Behcet\u2019s disease: association with disease activity and vascular involvement. J Clin Immunol 33:361\u2013367. https:\/\/doi.org\/10.1007\/s10875-012-9820-y","journal-title":"J Clin Immunol"},{"key":"5600_CR45","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.4049\/jimmunol.178.10.6567","volume":"178","author":"M Kitamura","year":"2007","unstructured":"Kitamura M, Iwabuchi K, Kitaichi N, Kon S, Kitamei H, Namba K, Yoshida K, Denhardt DT, Rittling SR, Ohno S, Uede T, Onoe K (2007) Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J Immunol 178:6567\u20136572. https:\/\/doi.org\/10.4049\/jimmunol.178.10.6567","journal-title":"J Immunol"},{"key":"5600_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.exer.2009.09.008","volume":"90","author":"D Iwata","year":"2010","unstructured":"Iwata D, Kitamura M, Kitaichi N, Saito Y, Kon S, Namba K, Morimoto J, Ebihara A, Kitamei H, Yoshida K, Ishida S, Ohno S, Uede T, Onoe K, Iwabuchi K (2010) Prevention of experimental autoimmune uveoretinitis by blockade of osteopontin with small interfering RNA. Exp Eye Res 90:41\u201348. https:\/\/doi.org\/10.1016\/j.exer.2009.09.008","journal-title":"Exp Eye Res"},{"key":"5600_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U","volume":"32","author":"P Saas","year":"2000","unstructured":"Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M, Desplat-Jego S, Chicheportiche Y, Dietrich PY (2000) TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 32:102\u2013107","journal-title":"Glia"},{"key":"5600_CR48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s1359-6101(03)00019-4","volume":"14","author":"SR Wiley","year":"2003","unstructured":"Wiley SR, Winkles JA (2003) TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR\/Fn14 receptor. Cytokine Growth Factor Rev 14:241\u2013249. https:\/\/doi.org\/10.1016\/s1359-6101(03)00019-4","journal-title":"Cytokine Growth Factor Rev"},{"key":"5600_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.14712\/18059694.2018.123","volume":"61","author":"A Icli","year":"2018","unstructured":"Icli A, Cure MC, Cure E, Arslan S, Unal M, Sakiz D, Ozucan M, Toker A, Turkmen K, Kucuk A (2018) Soluble tumor necrosis factor (TNF)-like weak inducer of apoptosis (Tweak) independently predicts subclinical atherosclerosis in Behcet\u2019s disease. Acta Medica (Hradec Kralove) 61:86\u201392. https:\/\/doi.org\/10.14712\/18059694.2018.123","journal-title":"Acta Medica (Hradec Kralove)"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05600-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T07:04:53Z","timestamp":1646118293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05600-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":49,"alternative-id":["5600"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05600-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"assertion":[{"value":"10 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Kyushu University Institutional Review Board for Clinical Research and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This work was approved by the Kyushu University Institutional Review Board for Clinical Research. Written informed consent was obtained from all the participants before any study procedures or examinations were performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data and photographs.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The funding sources had no role in the design and conduct of the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}